The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and ...

AstraZeneca, which is headquartered in the U.K. but reports its financials in U.S. dollars, earned just under $14.5 billion in its second quarter. That was a robust 12% higher year over year, and beat ...

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

Both AstraZeneca and Roche lifted their respective full-year profit guidances in light of strong quarterly financials released Thursday morning. For AstraZeneca, total revenue increased 17% at ...

AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular ...

“We study many, many things, many options, many strategies, many scenarios, 90% to 95% of what we study, we never put in place,” AstraZeneca CEO Pascal Soriot said when commenting on report of its ...